|
[1]
|
J. A. G. da Silva, “Estimate/2012—Cancer Incidence in Brazil,” National Cancer Institute, Rio de Janeiro, 2011.
http://www.inca.gov.br/estimativa/2012
|
|
[2]
|
A. N. Milne, R. Sitarz, R. Carvalho, et al., “Early Onset Gastric Cancer: On the Road to Unraveling Gastric Carcinogenesis,” Current Molecular Medicine, Vol. 7, No. 1, 2007, pp. 15-28. doi:10.2174/156652407779940503
|
|
[3]
|
A. N. Milne, R. Carvalho, F. M. Morsink, et al., “Early-Onset Gastric Cancers Have a Different Molecular Expression Profile than Conventional Gastric Cancers,” Modern Pathology, Vol. 19, No. 4, 2006, pp. 564-572.
doi:10.1038/modpathol.3800563
|
|
[4]
|
R. Carvalho, A. N. Milne, B. P. van Rees, et al., “Early-Onset Gastric Carcinomas Display Molecular Characteristics Distinct from Gastric Carcinomas Occurring at a Later Age,” The Journal of Pathology, Vol. 204, No. 1, 2004, pp. 75-83. doi:10.1002/path.1602
|
|
[5]
|
R. Santoro, F. Carboni, P. Lepiane, et al., “Clinicopathological Features and Prognosis of Gastric Cancer in Young European Adults,” British Journal of Surgery, Vol. 94, No. 6, pp. 737-742. doi:10.1002/bjs.5600
|
|
[6]
|
A. Jawhari, S. Jordan, S. Poole, et al., “Abnormal Immunoreactivity of the E-Cadherin-Catenin Complex in Gastric Carcinoma: Relationship with Patient Survival,” Gastroenterology, Vol. 112, No. 1, 1997, pp. 46-54.
doi:10.1016/S0016-5085(97)70218-X
|
|
[7]
|
M. Tanaka, Y. Kitajima, G. Edakuni, et al., “Abnormal Expression of E-Cadherin and Beta-Catenin May Be a Molecular Marker of Submucosal Invasion and Lymph Node Metastasis in Early Gastric Cancer,” British Journal of Surgery, Vol. 89, No. 2, 2002, pp. 236-244.
|
|
[8]
|
P. Guilford, J. Hopkins, J. Harraway, et al., “E-Cadherin Germline Mutations in Familial Gastric Cancer,” Nature, Vol. 392, No. 6674, 1998, pp. 402-405.
doi:10.1038/32918
|
|
[9]
|
C. Carrato, C. Balague, C. De Bolos, et al., “Differential Apomucin Expression in Normal and Neoplastic Human Gastrointestinal Tissues,” Gastroenterology, Vol. 107, No. 1, 1994, pp. 160-172.
|
|
[10]
|
S. B. Ho, L. L. Shekels, N. W. Toribara, et al., “Mucin Gene Expression in Normal, Pre-Neoplastic, and Neoplastic Human Gastric Epithelium,” Cancer Research, Vol. 55, No. 12, 1995, pp. 2681-2690.
|
|
[11]
|
E. M. Silva, M. D. Begnami, J. H. Fregnani, et al., “Cadherin-Catenin Adhesion System and Mucin Expression: A Comparison between Young and Older Patients with Gastric Carcinoma,” Gastric Cancer, Vol. 11, No. 3, 2008, pp. 149-159. doi:10.1007/s10120-008-0468-5
|
|
[12]
|
D. Malkin, F. P. Li, L. C. Strong, et al., “Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms,” Science, Vol. 250, No. 4985, 1990, pp. 1233-1238. doi:10.1126/science.1978757
|
|
[13]
|
J. M. Varley, “Germline TP53 Mutations and Li-Fraumeni Syndrome,” Human Mutation, Vol. 21, No. 3, 2003, pp. 313-320. doi:10.1002/humu.10185
|
|
[14]
|
F. Lalloo, J. Varley, D. Ellis, A. Moran, L. O’Dair, P. Pharoah and D. G. Evans, “Early Onset Breast Cancer Study Group. Prediction of Pathogenic Mutations in Patients with Early-Onset Breast Cancer by Family History,” Lancet, Vol. 361, No. 9363, 2003 pp. 1101-1102.
doi:10.1016/S0140-6736(03)12856-5
|
|
[15]
|
M. I. Achatz, M. Olivier, C. F. Le, et al., “The TP53 Mutation, R337H, Is Associated with Li-Fraumeni and Li-Fraumeni-Like Syndromes in Brazilian Families,” Cancer Letters, Vol. 245, No. 1-2, 2007, pp. 96-102.
doi:10.1016/j.canlet.2005.12.039
|
|
[16]
|
E. I. Palmero, L. Schüler-Faccini, M. Caleffi, M. I. Achatz, M. Olivier, G. Martel-Planche, V. Marcel, E. Aguiar, J. Giacomazzi, I. P. Ewald, R. Giugliani, P. Hainaut, P. Ashton-Prolla, “Detection of R337H, a Germline TP53 Mutation Predisposing to Multiple Cancers, in Asymptomatic Women Participating in a Breast Cancer Screening Program in Southern Brazil,” Cancer Letters, Vol. 261, No. 1, 2008, pp. 21-25. doi:10.1016/j.canlet.2007.10.044
|
|
[17]
|
S. Garritano, F. Gemignani, E. I. Palmero, et al., “Detailed Haplotype Analysis at the TP53 Locus in p.R337H Mutation Carriers in the Population of Southern Brazil: Evidence for a Founder Effect,” Human Mutation, Vol. 31, No. 2, 2010, pp. 143-150. doi:10.1002/humu.21151
|
|
[18]
|
E. M. da Silva, M. I. Achatz, G. Martel-Planche, et al., “TP53 mutation p.R337H in Gastric Cancer Tissues of a 12-Year-Old Male Child: Evidence for Chimerism Involving a Common Mutant Founder Haplotype: Case Report,” BMC Cancer, Vol. 11, 2011, p. 449.
doi:10.1186/1471-2407-11-449
|
|
[19]
|
L. H. Sobin, M. K. Gospodarowicz and C. Wittekind, “International Union against Cancer (UICC) TNM Classification of Malignant Tumours,” 7th edition, Wiley-Liss, New York, 2010, pp. 73-76.
|
|
[20]
|
P. Lauren, “The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification,” Acta Pathologica Microbiologica Scandinavica, Vol. 64, 1965, pp. 46-49.
|
|
[21]
|
C. P. Theuer, C. de Virgilio, G. Keese, et al., “Gastric Adenocarcinoma in Patients 40 Years of Age or Younger,” The American Journal of Surgery, Vol. 172, No. 5, 1996, pp. 473-476. doi:10.1016/S0002-9610(96)00223-1
|
|
[22]
|
H. Medina-Franco, M. J. Heslin and R. Cortes-Gonzalez, “Clinico Pathological Characteristics of Gastric Carcinoma in Young and Elderly Patients: A Comparative Study,” Annals of Surgical Oncology, Vol. 7, No. 7, 2000, pp. 515-519. doi:10.1007/s10434-000-0515-x
|
|
[23]
|
A. Ramos-De la Medina, N. Salgado-Nesme, G. Torres-Villalobos, et al., “Clinicopathologic Characteristics of Gastric Cancer in a Young Patient Population,” Journal of Gastrointestinal Surgery, Vol. 8, No. 3, 2004, pp. 240-244. doi:10.1016/j.gassur.2003.12.009
|
|
[24]
|
T. Yokota, N. Takahashi, S. Teshima, et al., “Early Gastric Cancer in the Young: Clinicopathological Study,” Australian and New Zealand Journal of Surgery, Vol. 69, No. 6, 1999, pp. 443-446.
doi:10.1046/j.1440-1622.1999.01553.x
|
|
[25]
|
J. H. van Krieken, M. Sasako and C. J. van de Vele, “Gastric Cancer,” In: M. K. Gospodarowicz, D. E. Henson and R. V. P. Hutter, B. O’Sullivan, L. H. Sobin and C. Wittekind, Eds., Prognostic Factors in Cancer, Wiley-Liss, New York, 2001, pp. 251-265.
|
|
[26]
|
T. C. Windham, P. M. Termuhlen, J. Ajani, et al., “Adenocarcinoma of the Stomach in Patients Age 35 Years and Younger: No Impact of Early Diagnosis on Survival Outcome,” Journal of Surgical Oncology, Vol. 81, No 3, 2002, pp. 118-124. doi:10.1002/jso.10157
|
|
[27]
|
H. Katai, M. Sasako, T. Sano, et al., “Gastric Carcinoma in Young Adults,” Japanese Journal of Clinical Oncology, Vol. 26, No. 3, 1996, pp. 139-143.
doi:10.1093/oxfordjournals.jjco.a023197
|
|
[28]
|
T. Eguchi, Y. Takahashi, M. Yamagata, et al., “Gastric Cancer in Young Patients,” Journal of the American College of Surgeons, Vol. 188, No. 1, 1999, pp. 22-26.
doi:10.1016/S1072-7515(98)00268-3
|
|
[29]
|
B. R. Smith and B. E. Stabile, “Extreme Aggressiveness and Lethality of Gastric Adenocarcinoma in the very Young,” Archives of Surgery, Vol. 144, No. 6, 2009, pp. 506-510. doi:10.1001/archsurg.2009.77
|
|
[30]
|
M. Rugge, Y. H. Shiao, G. Busatto, et al., “The p53 Gene in Patients under the Age of 40 with Gastric Cancer: Mutation Rates Are Low but Are Associated with a Cardiac Location,” Molecular Pathology, Vol. 53, No. 4, 2000, pp. 207-210. doi:10.1136/mp.53.4.207
|
|
[31]
|
A. M. Bunt, P. C. Hogendoorn, C. J. van de Velde, et al., “Lymph Node Staging Standards in Gastric Cancer,” Journal of Clinical Oncology, Vol. 13, No. 9, 1995, pp. 2309-2316.
|
|
[32]
|
M. Bjelovic, P. Pesko, M. Micev, et al., “The Significance of Lymphonodal Micrometastasis in the Patients with Gastric Adenocarcinoma,” Acta Chirurgica Iugoslavica, Vol. 52, No. 3, 2005, pp. 21-24.
doi:10.2298/ACI0503021B
|
|
[33]
|
S. Lim, H. S. Lee, H. S. Kim, et al., “Alteration of E-Cadherin-Mediated Adhesion Protein Is Common, but Microsatellite Instability Is Uncommon in Young Age Gastric Cancers,” Histopathology, Vol. 42, No. 2, 2003, pp. 128-136. doi:10.1046/j.1365-2559.2003.01546.x
|
|
[34]
|
C. M. Fenoglio-Preiser, J. Wang, et al., “TP53 and Gastric Carcinoma: A Review,” Human Mutation, Vol. 21, No. 3, 2003, pp. 258-270. doi:10.1002/humu.10180
|
|
[35]
|
Y. Yamada, T. Yoshida, K. Hayashi, et al., “p53 Gene Mutations in Gastric Cancer Metastases and in Gastric Cancer Cell Lines Derived from Metastases,” Cancer Research, Vol. 51, No. 21, 1991, pp. 5800-5805.
|
|
[36]
|
P. Correa and Y. Shiao, “Phenotypic and Genotypic Events in Gastric Carcinogenesis,” Cancer Research, Vol. 54, No. 7, 1994, pp. 1914s-1943s.
|
|
[37]
|
Y. Kakeji, D. Korenaga, S. Tsujitani, et al., “Gastric Cancer with p53 Overexpression Has High Potential for Metastasising to Lymph Nodes,” British Journal of Cancer, Vol. 67, No. 1, 1993, pp. 589-593.
doi:10.1038/bjc.1993.108
|
|
[38]
|
S. P. Monig, S. Eidt, T. K. Zirbes, et al., “p53 Expression in Gastric Cancer: Clinicopathological Correlation and Prognostic Significance,” Digestive Diseases and Sciences, Vol. 42, No. 12, 1997, pp. 2463-2467.
doi:10.1023/A:1018844008068
|
|
[39]
|
A. Bilici, M. Seker, B. B. O. Ustaalioglu, et al., “Prognostic Significance of Perineural Invasion in Patients with Gastric Cancer Who Underwent Curative Resection,” Annals of Surgical Oncology, Vol. 17, No. 8, 2010, pp. 2037-2044. doi:10.1245/s10434-010-1027-y
|
|
[40]
|
N. Duraker, S. Sisman and G. Can, “The Significance of Perineural Invasion As A Prognostic Factor In Patients With Gastric Carcinoma,” Surgery Today, Vol. 33, No. 2, 2003, pp. 95-100. doi:10.1007/s005950300020?
|
|
[41]
|
A. Tanaka, T. Watanabe, K. Okuno, et al., “Perineural Invasion as a Predictor of Recurrence of Gastric Cancer,” Cancer, Vol. 73, No. 3, 1994, pp. 550-555.
doi:10.1002/1097-0142(19940201)73:3<550::AID-CNCR2820730309>3.0.CO;2-0
|
|
[42]
|
Y. Maehara, M. Tomoda, S. Hasuda, et al., “Prognostic Value of p53 Protein Expression for Patients with Gastric Cancer—A Multivariate Analysis,” British Journal of Cancer, Vol. 79, No. 7-8, 1999, pp. 1255-1261.
doi:10.1038/sj.bjc.6690201
|
|
[43]
|
S. Kubicka, C. Claas, S. Staab, et al., “p53 Mutation Pattern and Expression of c-erbB2 and c-Met in gastric Cancer: Relation to Histological Subtypes, Helicobacter Pylori Infection, and Prognosis,” Digestive Diseases and Sciences, Vol. 47, No. 1, 2002, pp. 114-121.
doi:10.1023/A:1013275706401
|
|
[44]
|
H. E. Gabbert, W. Muller, A. Schneiders, et al., “The Relationship of p53 Expression to the Prognosis of 418 Patients with Gastric Carcinoma,” Cancer, Vol. 76, No. 5, 1995, pp. 720-726.
doi:10.1002/1097-0142(19950901)76:5<720::AID-CNCR2820760503>3.0.CO;2-E
|
|
[45]
|
H. S. Lee, H. K. Lee, H. S. Kim, et al., “Tumour Suppressor Gene Expression Correlates with Gastric Cancer Prognosis,” The Journal of Pathology, Vol. 200, No. 1, 2003, pp. 39-46. doi:10.1002/path.1288
|
|
[46]
|
S. E. Baldus, S. P. Monig, V. Arkenau, et al., “Correlation of MUC5AC Immunoreactivity with Histopathological Subtypes and Prognosis of Gastric Carcinoma,” Annals of Surgical Oncology, Vol. 9, No. 9, 2002, pp. 887-893. doi:10.1007/BF02557526
|
|
[47]
|
J. B. Koea, M. S. Karpeh and M. F. Brennan, “Gastric Cancer in Young Patients: Demographic, Clinicopathological, and Prognostic Factors in 92 Patients,” Annals of Surgical Oncology, Vol. 7, No. 5, 2000, pp. 346-351.
doi:10.1007/s10434-000-0346-9
|